These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 37122432)

  • 1. Role of antidiabetic agents in type 2 diabetes patients with chronic kidney disease.
    Lin WR; Liu KH; Ling TC; Wang MC; Lin WH
    World J Diabetes; 2023 Apr; 14(4):352-363. PubMed ID: 37122432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic Kidney Disease-Induced Insulin Resistance: Current State of the Field.
    Dave N; Wu J; Thomas S
    Curr Diab Rep; 2018 Jun; 18(7):44. PubMed ID: 29884917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
    Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance.
    Aroor AR; McKarns S; Demarco VG; Jia G; Sowers JR
    Metabolism; 2013 Nov; 62(11):1543-52. PubMed ID: 23932846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Roussel R; Lorraine J; Rodriguez A; Salaun-Martin C
    Adv Ther; 2015 Nov; 32(11):1029-64. PubMed ID: 26581749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin resistance in chronic kidney disease: a systematic review.
    Spoto B; Pisano A; Zoccali C
    Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1087-F1108. PubMed ID: 27707707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrial biogenesis: pharmacological approaches.
    Valero T
    Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
    Wish JB; Pergola P
    Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations.
    Górriz JL; Romera I; Cobo A; O'Brien PD; Merino-Torres JF
    Diabetes Ther; 2022 Mar; 13(3):389-421. PubMed ID: 35175551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of adipose tissue in chronic kidney disease development (Review).
    Miricescu D; Balan DG; Tulin A; Stiru O; Vacaroiu IA; Mihai DA; Popa CC; Enyedi M; Nedelea AS; Nica AE; Stefani C
    Exp Ther Med; 2021 May; 21(5):539. PubMed ID: 33815612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database.
    Fried L; Schmedt N; Folkerts K; Bowrin K; Raad H; Batech M; Kovesdy C
    Nephrol Dial Transplant; 2023 Feb; 38(3):630-643. PubMed ID: 35389468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of vitamin D in diabetes mellitus and chronic kidney disease.
    Nakashima A; Yokoyama K; Yokoo T; Urashima M
    World J Diabetes; 2016 Mar; 7(5):89-100. PubMed ID: 26981182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022.
    Hahr AJ; Molitch ME
    Am J Kidney Dis; 2022 May; 79(5):728-736. PubMed ID: 34600745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients.
    Vasquez-Rios G; Nadkarni GN
    Int J Nephrol Renovasc Dis; 2020; 13():281-296. PubMed ID: 33149657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment.
    Gangopadhyay KK; Singh P
    Indian J Endocrinol Metab; 2017; 21(2):341-354. PubMed ID: 28459036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin and its role in chronic kidney disease.
    Mak RH
    Pediatr Nephrol; 2008 Mar; 23(3):355-62. PubMed ID: 17929061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance in chronic kidney disease.
    Xu H; Carrero JJ
    Nephrology (Carlton); 2017 Dec; 22 Suppl 4():31-34. PubMed ID: 29155496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.